公开(公告)号：US12071660B2

公开(公告)日：2024-08-27

申请号：US16960510

申请日：2019-01-08

Applicant: Ludwig Institute for Cancer Research Ltd

Inventor： Chunxiao Song ,  Yibin Liu

IPC: C12Q1/68 ,  C12P17/16 ,  C12Q1/6844 ,  C12Q1/6869 ,  C12Q1/6874 ,  C12Q1/6876

CPC classification number: C12Q1/6869 ,  C12P17/16 ,  C12Q1/6844 ,  C12Q1/6874 ,  C12Q1/6876 ,  C12Q2600/154 ,  C12Y204/01026 ,  C12Y204/01027

Abstract: This disclosure provides methods for bisulfite-free identification in a nucleic acid sequence of the locations of 5-methylcytosine, 5-hydroxymethylcytosine, 5-carboxylcytosine and 5-formylcytosine.

公开(公告)号：US20240228966A1

公开(公告)日：2024-07-11

申请号：US18558802

申请日：2022-05-02

Applicant: SOCIETE DES PRODUITS NESTLE S.A. ,  LUDWIG INSTITUTE FOR CANCER RESEARCH LTD

Inventor： MUKUL GIROTRA ,  NICOLA VANNINI

IPC: C12N5/0789 ,  A61K35/28 ,  A61P7/06

CPC classification number: C12N5/0647 ,  A61K35/28 ,  A61P7/06 ,  C12N2501/999

Abstract: Use of a urolithin for increasing stem cell function in a population of haematopoietic stem and/or progenitor cells (HSPCs), wherein the stem cell function is increased for at least 40 weeks.

公开(公告)号：US20240117073A1

公开(公告)日：2024-04-11

申请号：US18307566

申请日：2023-04-26

Applicant: Ludwig Institute for Cancer Research Ltd.

Inventor： Lloyd J. Old ,  Terrance Grant Johns ,  Con Panousis ,  Andrew M. Scott ,  Christoph Renner ,  Gerd Ritter ,  Achim Jungbluth ,  Elisabeth Stockert ,  Vincent Peter Collins ,  Webster K. Cavenee ,  Huei-Jen Su Huang ,  Antony Wilks Burgess ,  Edouard C. Nice ,  Anne Murray ,  George Mark

IPC: C07K16/40 ,  A61K31/495 ,  A61K39/395 ,  A61K47/68 ,  A61K51/10 ,  C07K16/28 ,  C07K16/30 ,  C07K16/42

CPC classification number: C07K16/40 ,  A61K31/495 ,  A61K39/39541 ,  A61K39/39558 ,  A61K47/6871 ,  A61K51/103 ,  A61K51/1045 ,  A61K51/1078 ,  C07K16/2863 ,  C07K16/30 ,  C07K16/4258 ,  A61K2039/505

Abstract: The present invention relates to specific binding members, particularly antibodies and fragments thereof, which bind to amplified epidermal growth factor receptor (EGFR) and to the de2-7 EGFR truncation of the EGFR. In particular, the epitope recognized by the specific binding members, particularly antibodies and fragments thereof, is enhanced or evident upon aberrant post-translational modification. These specific binding members are useful in the diagnosis and treatment of cancer. The binding members of the present invention may also be used in therapy in combination with chemotherapeutics or anti-cancer agents and/or with other antibodies or fragments thereof.

公开(公告)号：US11946043B2

公开(公告)日：2024-04-02

申请号：US16645739

申请日：2018-09-11

Applicant: Ludwig Institute for Cancer Research Ltd

Inventor： Chunxiao Song ,  Paulina Siejka

IPC: C12N15/10 ,  C12Q1/6874

CPC classification number: C12N15/1065 ,  C12Q1/6874

Abstract: The present disclosure provides methods for selectively tagging 5-methylcytosine in a DNA sample and using this approach for genome-wide profiling of 5-methylcytosine in a low input DNA sample such as circulating cell-free DNA.

公开(公告)号：US20230414660A1

公开(公告)日：2023-12-28

申请号：US18252379

申请日：2021-11-12

Applicant: Ludwig Institute for Cancer Research Ltd ,  Centre Hospitalier Universitaire Vaudois ,  University of Lausanne

Inventor： George Coukos ,  Melita Irving ,  Vincent Zoete

IPC: A61K35/17 ,  A61K45/06 ,  C07K14/47 ,  A61P35/00

CPC classification number: A61K35/17 ,  A61K45/06 ,  C07K14/4747 ,  A61P35/00 ,  A61K38/00

Abstract: The present disclosure relates to novel PD-1 decoy variants, compositions, and methods to confer and/or increase immune responses mediated by cellular immunotherapy, such as by adoptively transferring tumor-specific genetically-modified subsets of lymphocytes.

公开(公告)号：US20220372149A1

公开(公告)日：2022-11-24

申请号：US17662518

申请日：2022-05-09

Applicant: AGENUS INC. ,  LUDWIG INSTITUTE FOR CANCER RESEARCH LTD. ,  MEMORIAL SLOAN-KETTERING CANCER CENTER

Inventor： Marc VAN DIJK ,  Cornelia Anne MUNDT ,  Gerd RITTER ,  Jedd David WOLCHOK ,  Taha MERGHOUB ,  Roberta ZAPPASODI ,  Rikke Baek HOLMGAARD ,  David SCHAER ,  David Adam SAVITSKY ,  Nicholas Stuart WILSON

IPC: C07K16/28 ,  A61P35/00 ,  A61K45/06 ,  A61K39/395

Abstract: The instant disclosure provides antibodies that specifically bind to human PD-1 and antagonize PD-1 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.

公开(公告)号：US11485780B2

公开(公告)日：2022-11-01

申请号：US16913067

申请日：2020-06-26

Applicant: LUDWIG INSTITUTE FOR CANCER RESEARCH, LTD.

Inventor： Jacques Van Snick ,  Catherine Uyttenhove

IPC: C07K16/22 ,  A61K47/68 ,  A61P35/00 ,  A61K39/395 ,  A61P35/04 ,  C07K16/30 ,  G01N33/574 ,  A61K45/06 ,  A61K39/00

Abstract: Specific binding members, particularly antibodies and fragments thereof, which bind to transforming growth factor beta 3 (TGF-β3) are provided, particularly recognizing human and mouse TGF-β3, particularly antibodies and fragments that do not recognize or bind TGF-β1 or TGF-β2. Particular antibodies are provided which specifically recognize and neutralize TGF-β3. These antibodies are useful in the diagnosis and treatment of conditions associated with activated or elevated TGF-β3, including cancer, and for modulating immune cells and immune response, including immune response to cancer or cancer antigens. The anti-TGF-β3 antibodies, variable regions or CDR domain sequences thereof, and fragments thereof may also be used in therapy in combination with chemotherapeutics, immune modulators, or anti-cancer agents and/or with other antibodies or fragments thereof. Antibodies of this type are exemplified by the novel antibodies hereof, including antibody MTGF-β3-9, MTGF-β3-12, MTGF-β3-16, MTGF-β3-17 and MTGF-β3-19, whose sequences are provided herein.

公开(公告)号：US20220267781A1

公开(公告)日：2022-08-25

申请号：US17630068

申请日：2020-07-24

Applicant: Ludwig Institute for Cancer Research Ltd ,  The Wistar Institute

Inventor： Zandra Walton ,  Zachary Stine ,  Yaoyu Gong ,  Chi Van Dang

IPC: C12N15/62 ,  A61K35/17 ,  C07K14/47 ,  C07K14/705 ,  C12N5/0783 ,  C12N9/12 ,  C12N9/88

Abstract: This disclosure provides methods for enhancing antitumor cytotoxicity of immune cells by introducing to the immune cells a genetic modification that comprises overexpression of RHEB or a functional fragment thereof, overexpression of LAMP 1-RHEB or a functional fragment thereof, overexpression of CA9 or a functional fragment thereof, overexpression of NHE1 or a functional fragment thereof, or combination thereof.

公开(公告)号：US20220227872A1

公开(公告)日：2022-07-21

申请号：US17613823

申请日：2020-05-29

Applicant: Ludwig Institute for Cancer Research Ltd ,  Centre Hospitalier Universitaire Vaudois ,  Université de Lausanne

Inventor： Steven M. Dunn ,  Julie K. Fierle ,  George Coukos

IPC: C07K16/28 ,  C07K14/705 ,  C07K14/725 ,  A61P35/00

Abstract: Provided herein are antibodies and antigen-binding portions thereof that bind to tumor endothelial marker 1 (TEM1), as well as methods of using the disclosed antibodies and antigen-binding portions thereof, including methods of treating cancer, reducing tumor growth, reducing tumor metastasis, and/or reducing tumor-associated fibrosis in a subject in need thereof.

公开(公告)号：US20220213543A1

公开(公告)日：2022-07-07

申请号：US17688424

申请日：2022-03-07

Applicant: Ludwig Institute for Cancer Research Ltd

Inventor： Chunxiao Song ,  Yibin Liu

IPC: C12Q1/6869 ,  C12P17/16 ,  C12Q1/6844 ,  C12Q1/6874 ,  C12Q1/6876

Abstract: This disclosure provides methods for bisulfite-free identification in a nucleic acid sequence of the locations of 5-methylcytosine, 5-hydroxymethylcytosine, 5-carboxylcytosine and 5-formylcytosine.